Compare GETY & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GETY | PRLD |
|---|---|---|
| Founded | 1995 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.6M | 312.2M |
| IPO Year | 2022 | 2020 |
| Metric | GETY | PRLD |
|---|---|---|
| Price | $0.77 | $4.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $3.78 | ★ $5.67 |
| AVG Volume (30 Days) | ★ 2.9M | 281.7K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $926,244,000.00 | $12,140,000.00 |
| Revenue This Year | $0.37 | $320.10 |
| Revenue Next Year | $1.47 | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 0.82 | ★ 73.43 |
| 52 Week Low | $0.67 | $0.75 |
| 52 Week High | $3.21 | $5.54 |
| Indicator | GETY | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 57.49 |
| Support Level | $0.71 | $3.92 |
| Resistance Level | $0.95 | $5.43 |
| Average True Range (ATR) | 0.08 | 0.31 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 19.62 | 97.30 |
Getty Images Holdings Inc. is a visual content creator and marketplace that offers a full range of content solutions. Through its Getty Images, Stock, and Unsplash brands, websites, and APIs, it serves customers around the world by allowing them to discover, purchase, and share visual content from photographers, illustrators, image partners, and videographers. The company generates a majority of its revenue through subscriptions, offering various subscription products on the Getty Images, iStock, and Unsplash websites. It operates and manages one operating segment, which is the business of developing and commercializing visual content. Geographically, the company generates maximum revenue from the Americas, followed by Europe, the Middle East and Africa, and the Asia-Pacific region.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.